Brokerages Set Amphastar Pharmaceuticals Inc (AMPH) Price Target at $23.73

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $23.73.

A number of analysts have commented on the stock. BidaskClub raised shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, May 10th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. TheStreet cut shares of Amphastar Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Monday, March 18th. Finally, Wells Fargo & Co reissued a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 10th.

In other news, SVP Yakob Liawatidewi sold 8,868 shares of the stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $23.86, for a total transaction of $211,590.48. Following the transaction, the senior vice president now owns 39,883 shares of the company’s stock, valued at approximately $951,608.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO William J. Peters sold 10,016 shares of the stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $24.37, for a total transaction of $244,089.92. Following the transaction, the chief financial officer now directly owns 85,566 shares in the company, valued at approximately $2,085,243.42. The disclosure for this sale can be found here. Insiders have sold a total of 100,017 shares of company stock worth $2,233,670 in the last three months. Insiders own 30.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers lifted its position in Amphastar Pharmaceuticals by 18.3% in the 4th quarter. Rhumbline Advisers now owns 103,943 shares of the company’s stock valued at $2,068,000 after acquiring an additional 16,080 shares in the last quarter. Renaissance Technologies LLC lifted its position in Amphastar Pharmaceuticals by 104.3% in the 3rd quarter. Renaissance Technologies LLC now owns 186,100 shares of the company’s stock valued at $3,581,000 after acquiring an additional 95,000 shares in the last quarter. MetLife Investment Advisors LLC lifted its position in Amphastar Pharmaceuticals by 54.3% in the 3rd quarter. MetLife Investment Advisors LLC now owns 28,086 shares of the company’s stock valued at $540,000 after acquiring an additional 9,881 shares in the last quarter. Rothschild & Co. Asset Management US Inc. lifted its position in Amphastar Pharmaceuticals by 4.3% in the 4th quarter. Rothschild & Co. Asset Management US Inc. now owns 335,930 shares of the company’s stock valued at $6,685,000 after acquiring an additional 13,757 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Amphastar Pharmaceuticals by 3.6% in the 3rd quarter. Legal & General Group Plc now owns 74,224 shares of the company’s stock valued at $1,425,000 after acquiring an additional 2,568 shares in the last quarter. 47.43% of the stock is currently owned by institutional investors and hedge funds.

AMPH traded down $0.07 during trading on Friday, reaching $20.94. 456 shares of the stock traded hands, compared to its average volume of 140,867. The company has a current ratio of 2.06, a quick ratio of 1.35 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $982.72 million, a P/E ratio of 99.50 and a beta of 1.36. Amphastar Pharmaceuticals has a 12 month low of $15.04 and a 12 month high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, May 9th. The company reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.07. The business had revenue of $79.79 million for the quarter, compared to analysts’ expectations of $76.21 million. Amphastar Pharmaceuticals had a net margin of 0.74% and a return on equity of 5.14%. The business’s quarterly revenue was up 36.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.05 earnings per share. As a group, research analysts predict that Amphastar Pharmaceuticals will post 0.46 EPS for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Recommended Story: Futures Contract

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.